10 August 2016

Endomagnetics Ltd (Endomag), the cancer healthcare spinout company from UCL, and Devicor Medical Products, a division of Leica Biosystems, are pleased to announce an exclusive distribution agreement of Endomag’s Sentimag, magnetic surgical guidance system, in the United States and Canada. This breakthrough technology provides a new standard of care for clinicians and breast cancer patients during surgical procedures.

This agreement greatly expands cancer patients’ access to care as the Sentimag system can be used by all hospitals by eliminating the need for radioactive tracers. The Sentimag system and its implantable magnetic seed, Magseed, guide surgeons to cancerous lesions easily and do not require the use of traditional surgical needle wires or radioactive seeds.  Similarly, the Sentimag system and its injectable iron solution, Sienna, is a replacement for the radioactive tracer and blue dye used in sentinel lymph node biopsies.

We are very excited to be the exclusive distributor of the Sentimag system in the United States and Canada,” said Alain de Lambilly, President of Leica Biosystems Tissue Acquisition Solutions business. “This technology represents a major advancement in breast cancer procedures for clinicians and helps to improve the overall standard of care received by patients everywhere. The Sentimag system fits in perfectly with our product portfolio and aligns with our mission of advancing cancer diagnostics, improving lives.

The agreement includes the Sentimag system, Magseed and Sienna in both the United States and Canada, pending regulatory approval within those markets.  The Sentimag system is approved in the U.S. and received its CE mark approval in 2010 and has already been used in over 14,000 breast care procedures across Europe.

Leica Biosystems is a leader in breast care, with products like the Mammotome breast biopsy system,” said Dr Eric Mayes, CEO of Endomag.  “We are truly thrilled for them to offer our products alongside theirs in the U.S. and Canada.  They have a world-class team and genuinely share our passion for improving lives, so are a natural partner to improve the standard of cancer care for everyone, everywhere.

About Endomagnetics Ltd
Endomag is a pioneer in the use of magnetism for minimally-invasive surgical guidance.  By addressing unmet needs in availability, affordability and workflow efficiency for surgical oncology, we support our mission to improve the global standard of cancer care for everyone, everywhere.  Founded as a spin-out from the University of Houston and the University College London (UCL) in 2007, we continue to develop our unique clinical platform that uses magnetic fields to power diagnostic and therapeutic devices.  The company has sales in over 30 countries worldwide and is headquartered in Cambridge, United Kingdom.

For more information, please visit endomag.com.

About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps.  Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture.  Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.

For more information, please visit mammotome.com or LeicaBiosystems.com.

LEICA and the Leica logo are registered trademarks of Leica Microsystems IR GmbH in certain countries. Mammotome is a registered trademark of Devicor Medical Products, Inc. in certain countries. Endomag, Sentimag and Sienna+ are registered trademarks of Endomagnetics Ltd. In certain countries.

About UCL Business PLC
UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market.

For further information, please visit: www.uclb.com – Twitter: @UCL_Business